The phase III NEMO study observed a similar PFS improvement with the MEK inhibitor binimetinib versus DTIC (HR 0.62; p < 0.001) in treatment-naïve or immunotherapy-pretreated patients with NRAS-mutant metastatic melanoma [16]. The gene discussed is MAP2K7; the disease is metastatic melanoma.